Artificial Intelligence-Enhanced Electrocardiography for Detection and Prediction of Hypertrophic Cardiomyopathy across Monogenic and Polygenic Susceptibility
Clinical AI moved from benchmarks toward deployment — and one paper flagged a gap between algorithmic scores and decisions.
TL;DR
- A medRxiv study evaluated AI-enhanced electrocardiography for detecting and predicting hypertrophic cardiomyopathy across monogenic and polygenic susceptibility.
- A PubMed study assessed a locally deployed vision language model for bone-tumor diagnosis on smartphone images, and another reported a multi-hospital federated-learning deployment in a regulator-audited environment.
- A PubMed paper described an 'alignment paradox' in medical LLMs in infertility care, where algorithmic improvement decoupled from clinical decision-making quality.
A medRxiv study evaluated AI-enhanced electrocardiography for detecting and predicting hypertrophic cardiomyopathy across monogenic and polygenic susceptibility. [1]
On the clinical-tool side, a PubMed study assessed a locally deployed vision language model for bone-tumor diagnosis using smartphone-captured images, and another reported a multi-hospital federated-learning deployment inside a regulator-audited secure processing environment. [2] [3]
Not all results point the same way: a PubMed paper described an 'alignment paradox' in medical LLMs in infertility care, where algorithmic improvement decoupled from clinical decision-making quality. [4]
Nature, meanwhile, reported that AI co-scientists are changing how research is done. [5]
Why it matters
The clinical-AI question is shifting from whether models can perform a task to whether they improve decisions under real deployment constraints — governance, data residency and the gap between benchmark scores and bedside outcomes.
Editor's note
Study results are cited at the abstract or article level and were not independently reviewed; the federated-learning deployment is a single multi-hospital study. No medical advice is offered.